Angiogenesis In Asthma: A Novel Potential Role For Il-25
W. Wang,Q. Meng,C. Fang,V. Reay,H.F. Wu,Y.Q. Fan,Z. Lv,Y.Q. An,Y.H. Wang,Y.J. Liu,T.H. Lee,C.J. Corrigan,S. Ying
DOI: https://doi.org/10.1016/j.jaci.2010.12.875
IF: 14.29
2011-01-01
Journal of Allergy and Clinical Immunology
Abstract:RATIONALE: IL-25 (IL-17E) is a Th2 type cytokine best described as a potentiator of Th2 memory responses. Reports of expression of its receptor, IL-25R, on airways structural cells suggest a wider role for IL-25 in remodelling. We hypothesized that IL-25 stimulates local angiogenesis in the asthmatic bronchial mucosa.METHODS: Immunoreactive IL-25+, IL-25R+ and CD31+ (endothelial) cells in sections of bronchial biopsies from asthmatics and controls were detected by immunohistochemistry. The effect of IL-25 on angiogenesis was examined using an in vitro assay. Real-time PCR was employed to detect expression of IL-25R and VEGF mRNA in cultured human umbilical vascular endothelial cells (HUVEC) and a WST-8 assay kit was used to measure effect of IL-25 on HUVEC proliferation.RESULTS: Immunostaining showed that IL-25+, IL-25R+ and CD31+/IL-25R+ cells were significantly elevated in the bronchial mucosa of asthmatics compared with controls (p<0.003). In the asthmatics, the numbers of IL-25+ cells correlated inversely with FEV1 (r=-0.639, p=0.01). In vitro, HUVEC constitutively expressed IL-25R which was further upregulated by TNF-α. IL-25 and TNF-α also increased expression of VEGF and VEGF receptors. IL-25 increased HUVEC proliferation and the numbers, lengths and areas of microvessel structures in a concentration dependent manner in vitro. VEGF blockade, the PI3K specific inhibitor LY294002 and the MEK 1/2 specific inhibitor U0126 all markedly attenuated IL-25-induced angiogenesis, while the inhibitors also reduced IL-25-induced proliferation and VEGF expression.CONCLUSION: IL-25 is elevated in asthma which might contribute to angiogenesis by increasing endothelial cell VEGF/VEGFR expression through PI3K/Akt and Erk/MAPK pathways. RATIONALE: IL-25 (IL-17E) is a Th2 type cytokine best described as a potentiator of Th2 memory responses. Reports of expression of its receptor, IL-25R, on airways structural cells suggest a wider role for IL-25 in remodelling. We hypothesized that IL-25 stimulates local angiogenesis in the asthmatic bronchial mucosa. METHODS: Immunoreactive IL-25+, IL-25R+ and CD31+ (endothelial) cells in sections of bronchial biopsies from asthmatics and controls were detected by immunohistochemistry. The effect of IL-25 on angiogenesis was examined using an in vitro assay. Real-time PCR was employed to detect expression of IL-25R and VEGF mRNA in cultured human umbilical vascular endothelial cells (HUVEC) and a WST-8 assay kit was used to measure effect of IL-25 on HUVEC proliferation. RESULTS: Immunostaining showed that IL-25+, IL-25R+ and CD31+/IL-25R+ cells were significantly elevated in the bronchial mucosa of asthmatics compared with controls (p<0.003). In the asthmatics, the numbers of IL-25+ cells correlated inversely with FEV1 (r=-0.639, p=0.01). In vitro, HUVEC constitutively expressed IL-25R which was further upregulated by TNF-α. IL-25 and TNF-α also increased expression of VEGF and VEGF receptors. IL-25 increased HUVEC proliferation and the numbers, lengths and areas of microvessel structures in a concentration dependent manner in vitro. VEGF blockade, the PI3K specific inhibitor LY294002 and the MEK 1/2 specific inhibitor U0126 all markedly attenuated IL-25-induced angiogenesis, while the inhibitors also reduced IL-25-induced proliferation and VEGF expression. CONCLUSION: IL-25 is elevated in asthma which might contribute to angiogenesis by increasing endothelial cell VEGF/VEGFR expression through PI3K/Akt and Erk/MAPK pathways.